Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Evaluation of aerosol drug delivery with concurrent low- and high-flow nasal oxygen

Barry Murphy, Marc Mac Giolla Eain, Mary Joyce, James B. Fink, Ronan MacLoughlin
ERJ Open Research 2022 8: 00220-2022; DOI: 10.1183/23120541.00220-2022
Barry Murphy
1Research and Development, Science & Emerging Technologies, Aerogen Limited, Galway, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Barry Murphy
Marc Mac Giolla Eain
1Research and Development, Science & Emerging Technologies, Aerogen Limited, Galway, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marc Mac Giolla Eain
Mary Joyce
1Research and Development, Science & Emerging Technologies, Aerogen Limited, Galway, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mary Joyce
James B. Fink
2Aerogen Pharma Corporation, San Mateo, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for James B. Fink
Ronan MacLoughlin
1Research and Development, Science & Emerging Technologies, Aerogen Limited, Galway, Ireland
3School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland
4School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ronan MacLoughlin
  • For correspondence: RMacLoughlin@aerogen.com
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Tables
  • Supplementary Materials
  • FIGURE 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1

    Schematic illustration of the experimental test facilities that were used to measure aerosol delivery (%) and fugitive medical aerosol emissions from aerosol therapy delivery using a mouthpiece and holding chamber with concurrent a) high-flow nasal oxygen and b) low-flow nasal oxygen. VMN: vibrating mesh nebuliser; OPS: optical particle sizer.

  • FIGURE 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2

    a) Aerosol drug delivery from a vibrating mesh nebuliser (VMN) at dry side of humidifier via cannula, and with aerosol holding chamber at 0, 2 and 6 L·min−1 during low-flow nasal oxygen (LFNO) at 0, 2, 3.5, 5, 7.5 and 10 L·min−1; and b) inhaled aerosol delivery efficiency (mean±sd %) at trachea from VMN at adapter and aerosol holding chamber at 0, 2 and 6 L·min−1 in model of spontaneously breathing adult patient with high-flow nasal oxygen (HFNO) gas flow of 10, 30, 50 and 60 L·min−1. MP: mouthpiece.

  • FIGURE 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3

    Mean aerosol concentrations against time measured at a) 0.8 m and b) 2.20 m with 0 L·min−1 supplemental air flow through the aerosol holding chamber and c) 0.8 m and d) 2.20 m with 6 L·min−1 supplemental air flow through the aerosol holding chamber. VMN: vibrating mesh nebuliser; MP: mouthpiece; LFNO: low-flow nasal oxygen; HFNO: high-flow nasal oxygen.

Tables

  • Figures
  • Supplementary Materials
  • TABLE 1

    Fugitive aerosol characterisation test details

    Supplemental air flow rate in aerosol chamber
    0 L·min−16 L·min−1
    LFNO circuit210210
    HFNO circuit10601060

    LFNO: low-flow nasal oxygen; HFNO: high-flow nasal oxygen.

    Supplementary Materials

    • Figures
    • Tables
    • Supplementary Material

      Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

      Supplementary material 00220-2022.SUPPLEMENT

    PreviousNext
    Back to top
    Vol 8 Issue 4 Table of Contents
    ERJ Open Research: 8 (4)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Evaluation of aerosol drug delivery with concurrent low- and high-flow nasal oxygen
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    Evaluation of aerosol drug delivery with concurrent low- and high-flow nasal oxygen
    Barry Murphy, Marc Mac Giolla Eain, Mary Joyce, James B. Fink, Ronan MacLoughlin
    ERJ Open Research Oct 2022, 8 (4) 00220-2022; DOI: 10.1183/23120541.00220-2022

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    Evaluation of aerosol drug delivery with concurrent low- and high-flow nasal oxygen
    Barry Murphy, Marc Mac Giolla Eain, Mary Joyce, James B. Fink, Ronan MacLoughlin
    ERJ Open Research Oct 2022, 8 (4) 00220-2022; DOI: 10.1183/23120541.00220-2022
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Abstract
      • Abstract
      • Introduction
      • Materials and methods
      • Results
      • Discussion
      • Supplementary material
      • Footnotes
      • References
    • Figures & Data
    • Info & Metrics
    • PDF

    Subjects

    • Pulmonary pharmacology and therapeutics
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Bacterial DNA amplifies neutrophilic inflammation in IL-17-exposed airways
    • PERSPIRE: a cohort study
    • Ipratropium bromide in EILO
    Show more Original research articles

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About ERJ Open Research

    • Editorial board
    • Journal information
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Online ISSN: 2312-0541

    Copyright © 2023 by the European Respiratory Society